Mental disorders are major causes of disability worldwide and rank as number one in terms of direct and indirect health economic costs as a recent ECNP commissioned report has demonstrated (Wittchen et al 2005). Depression, for instance, produces the greatest decrement in health compared with the common chronic diseases angina pectoris, arthritis, asthma, and diabetes (Moussavi et al., 2007) followed by addictive disorders (nicotine, alcohol, drugs). Unmet needs for mental health treatment today are pervasive all over the world and especially concerning in less-developed countries. A recent large worldwide study with 84.850 adults living in 17 low- to middle-income and high-income countries points out that although up to 30% of the population is expected to have clear-cut mental illness every year, in every one country studied, at least two-thirds of people who are mentally ill receive no treatment. In Europe, 27% of the population is affected by mental illness every year, but 74% is not treated, whereas only 8% of diabetics receives no care (Wittchen & Jacobi 2005; Wang et al., 2007; Thornicroft 2007). Thus, there is a compelling need to improve the fate of people struck by mental disorders, and vigorously reinforce the value of psychiatry and related disciplines for society.
20th ECNP Congress, Vienna
This week (13-17 October 2007) over 6000 psychiatrists, neurologists, psychologists and neuroscience researchers and practitioners from all over the world will join in Vienna at the 20th ECNP Congress to present and discuss the latest breakthroughs, the progress and the future perspectives in the fields of the origin and treatment of mental disorders, disorders of the brain, neuropsychopharmacology and related fields.
This largest high scientific standard meeting in Europe will provide all participants with the latest achievements and future perspectives in neuropsychopharmacology and closely related fields of virtually all disorders of the brain. The ECNP Congress is also expected to raise awareness about the size and burden of mental disorders in Europe and the availability of new treatments and to stimulate discussion about ways of implementing new knowledge and new therapeutic approaches.
The ECNP Congresses, playing a leading role in bringing together distinguished scientists identifying and testing promising new medications with novel mechanisms, are currently paving the groundwork for the next generation of pharmacological treatments, which will improve the lives of the millions of people who suffer from mental disorders.
Outstanding Highlights of the 20th ECNP Congress
Among the ECNP Congress extensive programmatic coverage of over 100 topics presented by over 600 experts, this years outstanding highlights are:
Invitation: Meet the scientists!
All the experts of the above listed themes will be available for questions by journalists in the course of topic specific press conferences on Sunday, Monday and Tuesday afternoon. You will find a detailed schedule of the press conferences in the enclosed Press information and procedures.
In addition, cutting edge research findings in the fields of Depression, Bipolar Affective Disorders, Schizophrenia, Anxiety Disorders, Obsessive Compulsive Disorder, Addiction and Basic Neuroscience will be presented in plenary lectures, educational updates and symposia, taking into account genetically related approaches as well as gender-specific aspects. Emphasis is placed on clear take-home-messages that can easily be transposed into clinical practice by medical professionals.
Due to the growing influence of health economic aspects on the treatment of mental illnesses, attention will be also drawn to the impact of publicly-funded mega-trials on clinical practice. Based on several recent trials the clinical and quality of life effects of psychopharmacologic treatments as well as their impact on the use and cost of medical services will be evaluated and discussed. ECNP hopes that this session will stimulate discussion of pharmaco-economic issues in psychiatry and will lead to greater physician involvement in the ongoing cost-management debates.
ECNP is also proud to present in the educational track the Report of the ECNP Consensus Meeting 2007 on the topic Bipolar depression. With annual consensus meetings on specific topics ECNP aims to facilitate the dialogue between the European regulatory authorities, the scientific community and the pharmaceutical industry in order to achieve a common policy in neuropsychopharmacology.
Paper submission again exceeded all expectations and has been accommodated by further increasing the number of posters. Overall, 730 papers were accepted for poster presentation offering an exciting insight into the research activities of young scientists and members of the ECNP. From the posters 12 will be selected to give an oral presentation during the Selected Poster Presentations (SPP) on Tuesday and Wednesday.
Outstanding scientists are nominated for the ECNP Neuropsychopharmacology Award. The ceremony for the winner of the ECNP Neuropsychopharmacology Award 2007 in Basic Science Research, E. Ron de Kloet will be held on Saturday 13 October, as part of the welcome ceremony.
|Contact: Sonja Mak|
European College of Neuropsychopharmacology